KMDA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

7.745

Open

7.720

VWAP

7.70

Vol

50.08K

Mkt Cap

444.18M

Low

7.660

Amount

385.73K

EV/EBITDA(TTM)

9.59

Total Shares

57.69M

EV

388.99M

EV/OCF(TTM)

15.13

P/S(TTM)

2.54

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Show More

Events Timeline

(ET)

2026-06-01

07:30:00

Kamada Receives FDA Approval for New RFFIT Laboratory

2026-05-13 (ET)

2026-05-13

07:50:00

Kamada Reports Q1 Revenue of $45.24M, Up 3% Year-over-Year

2026-05-13

07:50:00

Kamada Reiterates FY26 Adjusted EBITDA Guidance of $50M-$53M

2026-03-31 (ET)

2026-03-31

09:10:00

Kamada Obtains Tax Ruling for $0.25 Dividend per Share

2026-03-26 (ET)

2026-03-26

07:10:00

Kamada Receives FDA Approval for Plasma Collection Center in San Antonio, Texas

2026-03-11 (ET)

2026-03-11

16:30:00

Dow and S&P 500 Close Lower Amid Oil Price Volatility

2026-03-11

12:00:00

Dow Jones Drops Over 400 Points Amid Oil Price Volatility

2026-03-11

07:20:00

Kamada Reiterates 2026 Revenue Guidance of $200M to $205M

2026-03-11

07:10:00

Kamada Declares Cash Dividend of $0.25 per Share

2026-03-11

07:10:00

Kamada Reports 2025 Revenue of $180.5 Million, Up 12%

News

Newsfilter

06-01Newsfilter

PinnedKamada's New Laboratory Receives FDA Approval

NASDAQ.COM

06-01NASDAQ.COM

Kamada Receives FDA Approval for New Laboratory

seekingalpha

05-13seekingalpha

Kamada Releases 2026 Financial Guidance Amid Q1 Miss

seekingalpha

05-12seekingalpha

Kamada Q1 Earnings Announcement Scheduled

Newsfilter

03-31Newsfilter

Kamada Secures Tax Ruling for Dividend Distribution

seekingalpha

03-26seekingalpha

Kamada Receives FDA Approval for San Antonio Plasma Center

2 Analyst Rating

Wall Street analysts forecast KMDA stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

13.00

Averages

14.00

High

15.00

Current: 0.000

Low

13.00

Averages

14.00

High

15.00

H.C. Wainwright

Buy

maintain

$11 -> $13

AI Analysis

2025-12-09

Reason

H.C. Wainwright

Price Target

$11 -> $13

AI Analysis

2025-12-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Kamada to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a "long over-hanging distraction that was unlikely to be fruitful."

Valuation Metrics

The current forward P/E ratio for Kamada Ltd (KMDA.O) is 18.12, compared to its 5-year average forward P/E of 5.32. For a more detailed relative valuation and DCF analysis to assess Kamada Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

5.32

Current PE

18.12

Overvalued PE

14.16

Undervalued PE

-3.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

4.97

Current EV/EBITDA

3.78

Overvalued EV/EBITDA

8.41

Undervalued EV/EBITDA

1.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

1.90

Current PS

0.70

Overvalued PS

2.52

Undervalued PS

1.29

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

find sideways stocks for iron condor short

Intellectia · 32 candidates

Rsi Category: moderateBeta: LowRisk, ModerateRiskMonth Price Change Pct: $-3.00 - $3.00Is Optionable: TrueOption Iv Rank: 40 - 80

Ticker

Name

Market Cap$

T-Mobile US Inc

220.78B

Abeona Therapeutics Inc

280.98M

Theravance Biopharma Inc

1.01B

Vertex Pharmaceuticals Inc

118.96B

Best Buy Co Inc

14.09B

Ross Stores Inc

62.42B

Intellectia · 36 candidates

Market Cap: 300.00M - 1.20BPrice: $5.00 - $20.00Quarter Revenue Yoy Growth: >= 5.0%Pe Ttm: 8 - 25Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Radiant Logistics Inc

304.37M

Hudson Technologies Inc

308.76M

Waterstone Financial Inc

322.63M

Nexxen International Ltd

369.34M

Ponce Financial Group Inc

373.91M

Colony Bankcorp Inc

394.00M

Whales Holding KMDA

Phoenix Investments & Finances Ltd

Trading Trends

People Also Watch

Frequently Asked Questions

What is Kamada Ltd (KMDA) stock price today?

The current price of KMDA is 7.7 USD — it has decreased -1.41

What is Kamada Ltd (KMDA)'s business?

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

What is the price predicton of KMDA Stock?

Wall Street analysts forecast KMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMDA is14.00 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Kamada Ltd (KMDA)'s revenue for the last quarter?

Kamada Ltd revenue for the last quarter amounts to 45.24M USD, increased 2.78

What is Kamada Ltd (KMDA)'s earnings per share (EPS) for the last quarter?

Kamada Ltd. EPS for the last quarter amounts to 0.07 USD, decreased 0.00

How many employees does Kamada Ltd (KMDA). have?

Kamada Ltd (KMDA) has 393 emplpoyees as of June 02 2026.

What is Kamada Ltd (KMDA) market cap?

Today KMDA has the market capitalization of 444.18M USD.